Medical Treatment of Female Sexual Dysfunction.
Nappi. Rossella E RE; Tiranini. Lara L; Martini. Ellis E; Bosoni. David D; Righi. Alessandra A; Cucinella. Laura L
Key Findings
- Female sexual dysfunction is a complex, multi‑factor condition that requires a biopsychosocial approach.
- Flibanserin and bremelanotide (pt‑141) are FDA‑approved drugs for treating generalized acquired hypoactive sexual desire disorder in premenopausal women.
- Transdermal testosterone and menopause hormone therapy are effective for postmenopausal women with low desire.
Practical Outcomes
- For biohackers interested in boosting sexual desire, bremelanotide is a clinically validated peptide for premenopausal women with HSDD. Use the approved dosing schedule (e.g., 1.75 mg subcutaneous injection as needed) and monitor side effects. Post‑menopausal individuals should consider testosterone or hormone therapy instead. Always consult a healthcare professional before self‑administering.
Summary
Female sexual problems are common and have many causes. Doctors first screen and give basic advice, then may use drugs or other methods. For women before menopause with low sexual desire, two pills are approved: flibanserin and the peptide bremelanotide (pt‑141). After menopause, testosterone patches and hormone therapy are the main options.
Abstract
Female sexual dysfunction (FSD) comprises multiple overlapping sexual disorders with a multifaceted cause within the frame of the biopsychosocial model. Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually referring to sexual medicine specialists for specific care. The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, whereas transdermal testosterone is effective on HSDD in postmenopausal women. Menopause hormone therapy (systemic and local) is the mainstay for individualized management of women at midlife.
Study Information
pubmed
2022
2022-05-01T00:00:00.000Z
10.1016/j.ucl.2022.02.001
28
81